



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Norursodeoxycholic Acid

Item No. 33925

CAS Registry No.: 99697-24-2
Formal Name: (3 α ,5 β ,7 β)-3,7-dihydroxy-24-norcholan-23-oic acid

Synonyms: norUDCA, 24-Norursodeoxycholic Acid, Nourcholic Acid

MF: C₂₃H₃₈O₄


FW: 378.6

Purity: \geq 98%

Supplied as: A solid

Storage: -20°C

Stability: \geq 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Norursodeoxycholic acid (norUDCA) is supplied as a solid. A stock solution may be made by dissolving the norUDCA in the solvent of choice, which should be purged with an inert gas. norUDCA is soluble in DMSO.

Description

norUDCA is a bile acid and the C23 homolog of UDCA (Item No. 15121).^{1,2} Unlike UDCA, norUDCA does not undergo conjugation to taurine or glycine and is secreted in an unchanged form, as trihydroxy derivatives, or as sulfate or glucuronide conjugates. Dietary administration of norUDCA (0.5% w/w) decreases serum levels of alanine aminotransferase (ALT) and alkaline phosphatase, markers of cholestasis, periductal fibrosis, and hepatic hydroxyproline content in an *Mdr2*^{-/-} mouse model of sclerosing cholangitis.¹

References

1. Fickert, P., Wagner, M., Marschall, H.-U., *et al.* 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in *Mdr2* (*Acb4*) knockout mice. *Gastroenterology* **130**(2), 465-481 (2006).
2. Hofmann, A.F., Zakko, S.F., Lira, M., *et al.* Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. *Hepatology* **42**(6), 1391-1398 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/24/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM